Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Eckstein

Showing results (11-20 of 261) with videos related to

Pageof 27
Sort By:
Advances in Anatomic Pathology|February 2, 2023
Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive FactorsVeronika Bahlinger, Arndt Hartmann, Markus Eckstein
European Urology|May 27, 2023
Reply to Mattias Höglund's Letter to the Editor re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020Niklas Klümper, Alexander Cox, Markus Eckstein
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Assessment of PD-L1 Status in Urothelial CancerVeronika Bahlinger, Arndt Hartmann, Markus Eckstein
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Evaluation of FGFR Alteration Status in Urothelial TumorsVeronika Bahlinger, Markus Eckstein, Arndt Hartmann, et al.
Current Drug Targets|May 11, 2020
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future PerspectivesThomas Gevaert, Alessia Cimadamore, Rodolfo Montironi, et al.
Current Drug Targets|March 28, 2020
PD1/PD-L1 Axis in Uro-oncologyKerstin Junker, Markus Eckstein, Michelangelo Fiorentino, et al.
Pathologie (Heidelberg, Germany)|April 30, 2026
[Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future]Sebastian Rauch, Fabienne Lange, Arndt Hartmann, et al.
Aktuelle Urologie|July 1, 2025
[Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology]Günter Niegisch, Stefanie Zschäbitz, Niklas Klümper, et al.
Urologie (Heidelberg, Germany)|January 28, 2026
[From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma]Günter Niegisch, Stefanie Zschäbitz, Markus Eckstein, et al.
European Urology|July 16, 2018
Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder CancerMarkus Eckstein, Danijel Sikic, Pamela L Strissel, et al.
Pageof 27

Showing results (11-20 of 261) with videos related to

Sort By:
Pageof 27
Advances in Anatomic Pathology|February 2, 2023
Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive FactorsVeronika Bahlinger, Arndt Hartmann, Markus Eckstein
European Urology|May 27, 2023
Reply to Mattias Höglund's Letter to the Editor re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020Niklas Klümper, Alexander Cox, Markus Eckstein
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Assessment of PD-L1 Status in Urothelial CancerVeronika Bahlinger, Arndt Hartmann, Markus Eckstein
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Evaluation of FGFR Alteration Status in Urothelial TumorsVeronika Bahlinger, Markus Eckstein, Arndt Hartmann, et al.
Current Drug Targets|May 11, 2020
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future PerspectivesThomas Gevaert, Alessia Cimadamore, Rodolfo Montironi, et al.
Current Drug Targets|March 28, 2020
PD1/PD-L1 Axis in Uro-oncologyKerstin Junker, Markus Eckstein, Michelangelo Fiorentino, et al.
Pathologie (Heidelberg, Germany)|April 30, 2026
[Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future]Sebastian Rauch, Fabienne Lange, Arndt Hartmann, et al.
Aktuelle Urologie|July 1, 2025
[Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology]Günter Niegisch, Stefanie Zschäbitz, Niklas Klümper, et al.
Urologie (Heidelberg, Germany)|January 28, 2026
[From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma]Günter Niegisch, Stefanie Zschäbitz, Markus Eckstein, et al.
European Urology|July 16, 2018
Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder CancerMarkus Eckstein, Danijel Sikic, Pamela L Strissel, et al.
Pageof 27